Details for Patent: 9,023,389

Which drugs does patent 9,023,389 protect, and when does it expire?

Patent 9,023,389 protects JORNAY PM and is included in one NDA.

This patent has thirty-seven patent family members in fourteen countries.

Summary for Patent: 9,023,389

Title:	Compositions for treatment of attention deficit hyperactivity disorder
Abstract:	Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
Inventor(s):	Lickrish; David (Grand Cayman, KY), Zhang; Feng (Pflugerville, TX)
Assignee:	Ironshore Pharmaceuticals & Development, Inc. (Camana Bay, KY)
Application Number:	14/589,839
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 9,023,389

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ironshore Pharms	JORNAY PM	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	209311-001	Aug 8, 2018		RX	Yes	No			Y
Ironshore Pharms	JORNAY PM	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	209311-002	Aug 8, 2018		RX	Yes	No			Y
Ironshore Pharms	JORNAY PM	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	209311-003	Aug 8, 2018		RX	Yes	No			Y

International Family Members for US Patent 9,023,389

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012230733
Australia	2016228307
Australia	2018202002